静脉输注利多卡因对全麻效果影响的研究

注册号:

Registration number:

ChiCTR2300069112 

最近更新日期:

Date of Last Refreshed on:

2023-07-03 17:08:57 

注册时间:

Date of Registration:

2023-03-07 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

静脉输注利多卡因对全麻效果影响的研究

Public title:

Study on the effect of intravenous lidocaine on general anesthesia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

静脉输注利多卡因对全麻效果影响的研究

Scientific title:

Study on the effect of intravenous lidocaine on general anesthesia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李梦鸽 

研究负责人:

郭志佳 

Applicant:

Mengge Li 

Study leader:

Zhijia Guo 

申请注册联系人电话:

Applicant telephone:

+86 176 3405 6698

研究负责人电话:

Study leader's
telephone:

+86 138 3467 6473

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1044104543@qq.com

研究负责人电子邮件:

Study leader's E-mail:

guozj11@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山西医科大学

研究负责人通讯地址:

山西医科大学第一医院麻醉科

Applicant address:

Shanxi Medical University

Study leader's address:

Department of Anesthesiology,The First Hospital of Shanxi Medical University

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山西医科大学

Applicant's institution:

Shanxi Medical University

研究负责人所在单位:

山西医科大学第一医院麻醉科

Affiliation of the Leader:

Department of Anesthesiology, The First Hospital of Shanxi Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

NO.KYLL-2023-003

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山西医科大学第一医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Hospital of Shanxi Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-01-12 00:00:00

伦理委员会联系人:

智陞雯

Contact Name of the ethic committee:

Shengwen Zhi

伦理委员会联系地址:

山西省太原市迎泽区解放南路85号

Contact Address of the ethic committee:

85 Jiefang Nan Lu, Yingze District, Taiyuan, Shanxi, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 351 463 9021

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山西医科大学第一医院

Primary sponsor:

The First Hospital of Shanxi Medical University

研究实施负责(组长)单位地址:

山西省太原市迎泽区解放南路85号

Primary sponsor's address:

85 Jiefang Nan Lu, Yingze District, Taiyuan, Shanxi, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

太原市

市(区县):

迎泽区

Country:

China

Province:

Taiyuan

City:

Yingze

单位(医院):

山西医科大学第一医院

具体地址:

山西省太原市迎泽区解放南路85号

Institution
hospital:

The First Hospital of Shanxi Medical University

Address:

85 Jiefang Nan Lu, Yingze District, Taiyuan, Shanxi, China

经费或物资来源:

学校研究生科研经费

Source(s) of funding:

Research funds for graduate students

研究疾病:

全身麻醉效果  

Target disease:

Effect of general anesthesia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

拟通过研究静脉输注利多卡因,探讨其对全麻患者术中各项监测指标、术后恢复质量、远期预后的影响及相关机制  

Objectives of Study:

It is intended to study the influence of intravenous lidocaine on various intraoperative monitoring indexes, postoperative recovery quality and long-term prognosis of patients with general anesthesia, as well as the related mechanism.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.已知对利多卡因等酰胺类局麻药过敏者;
2.合并严重的心血管系统疾病的患者;
3.合并肝肾功能异常的患者;
4.合并有脑血管病的患者;
5.合并有精神类疾病的患者;
6.在前2周内长期使用阿片类药物、苯二氮卓类药物、非甾体抗炎药或任何作用于中枢神经系统的药物、药物滥用/酒精滥用等;
7.术前两周合并有呼吸道感染的患者。

Exclusion criteria:

1. Known allergy to local anesthetics such as lidocaine;
2. Patients with severe cardiovascular disease;
3. Patients with abnormal liver and kidney function;
4. Patients with cerebrovascular disease;
5. Patients with mental diseases;
6. Chronic use of opioids, benzodiazepines, NSaids or any drug that acts on the central nervous system, drug abuse/alcohol abuse, etc., in the previous 2 weeks;
7. Patients with respiratory tract infection two weeks before surgery.

研究实施时间:

Study execute time:

From 2023-03-01 00:00:00 To 2024-03-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-03-09 00:00:00 To 2023-08-01 00:00:00

干预措施:

Interventions:

组别:

L组

样本量:

125

Group:

L group

Sample size:

干预措施:

静脉输注利多卡因1-2 mg/kg/h

干预措施代码:

Intervention:

Intravenous infusion of lidocaine 1-2 mg/kg/h

Intervention code:

组别:

C组

样本量:

125

Group:

C group

Sample size:

干预措施:

输注同等体积生理盐水

干预措施代码:

Intervention:

The same volume of normal saline was transfused

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

太原 

市(区县):

迎泽区 

Country:

China

Province:

Taiyuan

City:

Yingze

单位(医院):

山西医科大学第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Hospital of Shanxi Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

神经电生理监测指标(IONM电极阻抗值等)

指标类型:

主要指标

Outcome:

Neuroelectrophysiological monitoring indexes (IONM electrode impedance, etc.)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体温(鼻咽温、肛温、腋温等)

指标类型:

主要指标

Outcome:

Body temperature (nasopharyngeal temperature, anal temperature, axillary temperature, etc.)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后咽痛评分

指标类型:

主要指标

Outcome:

Postoperative pharyngeal pain score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后首次排气或排便时间

指标类型:

主要指标

Outcome:

Time of first postoperative exhaust or defecation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血流动力学参数(血压、心率等)

指标类型:

次要指标

Outcome:

Hemodynamic parameters (blood pressure, heart rate, etc.)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

呼吸力学参数

指标类型:

次要指标

Outcome:

Respiratory mechanical parameter

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

各系统并发症发生率

指标类型:

次要指标

Outcome:

Complication rate of each system

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

咽部分泌物

组织:

咽部

Sample Name:

Pharyngeal secretions

Tissue:

pharyngeal

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数表法

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

单盲

Blinding:

single blind

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

实验完成后即时公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The experiment will be made public immediately after completion.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-03-07 14:30:15